Published in Anti-Infectives Week, April 26th, 2004
The company has accepted approximately $2 million of the subscriptions in the initial closing and will receive the remaining $14.5 million upon receipt of shareholder approval to issue the shares offered to investors.
New York, New York-based Paramount BioCapital, Inc., served as the placement agent for this financing.
To complete the private placement, InSite Vision will require approval by its shareholders to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Anti-Infectives Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.